Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms FOCUS
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 17 Dec 2018 According to a Teva Pharmaceutical Industries media release, the company plans to submit the full results from this study for medical meetings in 2019, as well as peer-reviewed publication..
    • 17 Dec 2018 Results presented in a Teva Pharmaceutical Industries media release.
    • 13 Oct 2018 Planned End Date changed from 30 Sep 2019 to 6 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top